secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001193125-26-135767
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences reports FY2025 net loss $69.4M, cash $77M; celiac Phase 2 data due 2026
--------------------------------------------------------------------------------

- Net loss $69.4M ($4.71/shr) vs $35.5M ($12.17/shr) in 2024; R&D expenses $58.2M, up from $21.2M.
- Cash and equivalents $77.0M at Dec 31, 2025, up from $22.2M at Dec 31, 2024.
- Phase 2 celiac disease topline data expected in 2026; Phase 1b vitiligo (1H 2026) and alopecia areata data expected in 2026.
- Weighted average shares & pre-funded warrants 14.7M vs 2.9M in 2024; CEO highlights FB102 potential in multi-billion markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526135767/0001193125-26-135767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526135767/d63145d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-135767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer